RxDoctor Payments Data

Matthew Wilner, MD

Urology · Plano, TXNPI 1245284785

Payments from drug & device makers

$66,559in general payments, 2019–2025

Across 85 payments — averaging $783.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$62K
  • Pfizer$1K
  • Teleflex LLC$1K
  • Neotract Inc.$874
  • Astellas Pharma US Inc$213
  • Boston Scientific$166
  • plus $923 from 21 others

What the payments were for

  • Travel & lodging$1,35240%
  • Food & beverage$1,91356%
  • Education$1444%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,559 in reported general payments places this provider in the 90th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$921,310
Medicare patients
1,238
Services billed
32,182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide180$2,446,430
ErleadaApalutamide30$433,489
NubeqaDarolutamide18$237,385
OrgovyxRelugolix82$216,307
MyrbetriqMirabegron218$188,651
GemtesaVibegron24$31,446
Methenamine Hippurate184$22,249
Tamsulosin Hcl1,125$18,451
Mirabegron ErMirabegron21$15,470
Abiraterone Acetate12$12,264
Finasteride750$11,267
Potassium Citrate ErPotassium Citrate56$8,283
Testosterone25$5,712
Dutasteride60$4,660
Solifenacin Succinate90$3,492

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$213$2,635,080398 claims
Johnson & JohnsonErleada$85$433,48930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 urology providers in Texas.

Other urology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →